section name header

Pronunciation ⬇

pal-i-VI-zoo-mab

Classifications ⬆ ⬇

Therapeutic Classification: antivirals

Pharmacologic Classification: monoclonal antibodies

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Neutralizes and inhibits fusion of RSV virus; subsequently inhibits viral replication.
Therapeutic effects:
  • Prevents serious sequelae of RSV disease in susceptible children.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after IM administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 20 days.

Time/Action Profile ⬆ ⬇

(antibody levels)

ROUTEONSETPEAKDURATION
IMrapid48 hr30 days



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

Hemat: thrombocytopenia

Local: erythema, induration

Neuro: fever

Misc: ANAPHYLACTOID REACTIONS AND ANAPHYLAXISHYPERSENSITIVITY REACTIONS INCLUDING

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Synagis